RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of TGTX
Powered by GPT-4o
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Green day on Tuesday for TG Therapeutics
(Updated on Jul 02, 2024)

Buy candidate since Jun 18, 2024 Gain 9.18% PDF

The TG Therapeutics stock price gained 0.88% on the last trading day (Tuesday, 2nd Jul 2024), rising from $18.15 to $18.31. During the last trading day the stock fluctuated 3.71% from a day low at $17.79 to a day high of $18.45. The price has risen in 8 of the last 10 days and is up by 10.5% over the past 2 weeks. Volume fell on the last day by -289 thousand shares and in total, 2 million shares were bought and sold for approximately $34.17 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 25.04% during the next 3 months and, with a 90% probability hold a price between $20.12 and $24.39 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

TGTX Signals & Forecast

The TG Therapeutics stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $18.22 and $17.03. A breakdown below any of these levels will issue sell signals. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Tuesday, June 25, 2024, and so far it has fallen -4.59%. Further fall is indicated until a new bottom pivot has been found.

Support, Risk & Stop-loss for TG Therapeutics stock

TG Therapeutics finds support from accumulated volume at $17.65 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.660 between high and low, or 3.71%. For the last week, the stock has had daily average volatility of 5.52%.

Our recommended stop-loss: $17.68 (-3.42%) (This stock has medium daily movements and this gives medium risk. There is a sell signal from a pivot top found 17 days ago.)

Trading Expectations (TGTX) For The Upcoming Trading Day Of Wednesday 3rd

For the upcoming trading day on Wednesday, 3rd we expect TG Therapeutics to open at $18.18, and during the day (based on 14 day Average True Range), to move between $17.43 and $19.19, which gives a possible trading interval of +/-$0.88 (+/-4.81%) up or down from last closing price. If TG Therapeutics takes out the full calculated possible swing range there will be an estimated 9.61% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $18.41 (0.55%) than the support at $17.65 (3.60%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is TG Therapeutics stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for TG Therapeutics stock to perform well in the short-term.

Current score: 3.662 Buy Candidate Unchanged

Predicted Opening Price for TG Therapeutics of Wednesday, July 3, 2024

Fair opening price July 3, 2024 Current price
$18.18 ( 0.692%) $18.31

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for TGTX

Fibonacci Support & Resistance Levels

Level Price
R3 18.84 2.91%
R2 18.59 1.54%
R1 18.44 0.685%
Price 18.31
S1 17.93 -2.07%
S2 17.78 -2.92%
S3 17.52 -4.30%

Accumulated Volume Support & Resistance Levels

Level Price
R3 0 -
R2 19.19 4.81%
R1 18.41 0.546%
Price 18.31
S1 17.65 -3.60%
S2 16.42 -10.32%
S3 15.88 -13.27%

FAQ

What is the symbol for TG Therapeutics Stock and on which exchange is it traded?
The symbol for TG Therapeutics is TGTX and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell TG Therapeutics Stock?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for TG Therapeutics stock to perform well in the short-term.

How to buy TG Therapeutics Stock?
TG Therapeutics Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy TG Therapeutics Stock.

What's the current price of TG Therapeutics Stock?
As of the end of day on the Jul 02, 2024, the price of an TG Therapeutics (TGTX) share was $18.31.

What is the 52-week high and low for TG Therapeutics Stock?
The 52-week high for TG Therapeutics Stock is $26.95 and the 52-week low is $6.47.

What is the market capitalization of TG Therapeutics Stock?
As of the Jul 02, 2024, the market capitalization of TG Therapeutics is 2.805B.

When is the next earnings date for TG Therapeutics?
The upcoming earnings date for TG Therapeutics is Aug 06, 2024.
Click to get the best stock tips daily for free!

About TG Therapeutics

TG Therapeutics TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbra... TGTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT